Panax quinquefolius polysaccharides ameliorate ulcerative colitis in mice induced by dextran sulfate sodium

This study aimed to investigate the ameliorative effect of the polysaccharides of Panax quinquefolius (WQP) on ulcerative colitis (UC) induced by dextran sulfate sodium (DSS) in mice and to explore its mechanism. Male C57BL/6J mice were randomly divided into the control group (C), model group (DSS), positive control mesalazine (100 mg/kg, Y) group, and low (50 mg/kg, L), medium (100 mg/kg, M) and high dose (200 mg/kg, H) of WQP groups. The UC model was induced by free drinking water with 2.5% DSS for 7 days. During the experiment, the general condition of the mice was observed, and the disease activity index (DAI) was scored. The conventional HE staining was used to observe pathological changes in mice’s colon, and the ELISA method was used to detect the levels of interleukin-6 (IL-6), IL-4, IL-8, IL-10, IL-1β and tumor necrosis factor-α (TNF-α) in mice’s colon. The changes in gut microbiota in mice were detected by high-throughput sequencing; the concentration of short-chain fatty acids (SCFAs) was determined by gas chromatography; the expression of related proteins was detected by Western blot. Compared with the DSS group, the WQP group showed a significantly lower DAI score of mice and an alleviated colon tissue injury. In the middle- and high-dose polysaccharides groups, the levels of pro-inflammatory cytokines IL-6, IL-8, IL-1β and TNF-α in the colonic tissue were significantly decreased (P<0.05), while the levels of IL-4 and IL-10 were significantly increased (P<0.05). The 16S rRNA gene sequencing results showed that different doses of WQP could regulate the composition and diversity of gut microbiota and improve its structure. Specifically, at the phylum level, group H showed an increased relative abundance of Bacteroidetes and a decreased relative abundance of Firmicutes compared with the DSS group, which was closer to the case in group C. At the family level, the relative abundance of Rikenellaceae in L, M and H groups increased significantly, close to that in group C. At the genus level, the relative abundance of Bacteroides, Shigella and Oscillospira in the H group increased significantly, while that of Lactobacillus and Prevotella decreased significantly. The high-dose WQP group could significantly increase the contents of acetic acid, propionic acid, butyric acid, and total SCFAs. Different doses of WQP also increased the expression levels of tight junction proteins ZO-1, Occludin and Claudin-1. To sum up, WQP can regulate the gut microbiota structure of UC mice, accelerate the recovery of gut microbiota, and increase the content of Faecal SCFAs and the expression level of tight junction proteins in UC mice. This study can provide new ideas for the treatment and prevention of UC and theoretical references for the application of WQP.

[1]  F. Marques,et al.  How Dietary Fibre, Acting via the Gut Microbiome, Lowers Blood Pressure , 2022, Current Hypertension Reports.

[2]  Duo-duo Ren,et al.  Panax quinquefolius Polysaccharides Ameliorate Antibiotic-Associated Diarrhoea Induced by Lincomycin Hydrochloride in Rats via the MAPK Signaling Pathways , 2022, Journal of immunology research.

[3]  R. Ashour,et al.  Pentosan Polysulfate Sodium augments the therapeutic effect of 5-Aminosalicylic Acid in DSS colitis model; the role of IL-35 expression. , 2022, International immunopharmacology.

[4]  Yinshi Sun,et al.  The Protective Effects of Ginseng Polysaccharides and Their Effective Subfraction against Dextran Sodium Sulfate-Induced Colitis , 2022, Foods.

[5]  Dake Cai,et al.  Natural-derived alkaloids exhibit great potential in the treatment of ulcerative colitis. , 2021, Pharmacological research.

[6]  Chengjie Guo,et al.  Ganoderma lucidum polysaccharide modulates gut microbiota and immune cell function to inhibit inflammation and tumorigenesis in colon. , 2021, Carbohydrate polymers.

[7]  Xiuqi Zhang,et al.  Crataegus pinnatifida polysaccharide alleviates colitis via modulation of gut microbiota and SCFAs metabolism. , 2021, International journal of biological macromolecules.

[8]  Le Zhang,et al.  Dietary Taxifolin Protects Against Dextran Sulfate Sodium-Induced Colitis via NF-κB Signaling, Enhancing Intestinal Barrier and Modulating Gut Microbiota , 2021, Frontiers in Immunology.

[9]  Daqing Zhao,et al.  Recent progress in polysaccharides from Panax ginseng C. A. Meyer. , 2020, Food & function.

[10]  Yiqing Ye,et al.  The role of short-chain fatty acids in immunity, inflammation and metabolism , 2020, Critical reviews in food science and nutrition.

[11]  Jie Song,et al.  Scutellaria baicalensis Georgi polysaccharide ameliorates DSS-induced ulcerative colitis by improving intestinal barrier function and modulating gut microbiota. , 2020, International journal of biological macromolecules.

[12]  C. K. Yao,et al.  Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  A. Farone,et al.  Panax quinquefolius (North American ginseng) cell suspension culture as a source of bioactive polysaccharides: Immunostimulatory activity and characterization of a neutral polysaccharide AGC1. , 2019, International journal of biological macromolecules.

[14]  K. Faber,et al.  Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases , 2019, Front. Immunol..

[15]  Jana G Hashash,et al.  A comprehensive review and update on ulcerative colitis. , 2019, Disease-a-month : DM.

[16]  D. Sohn,et al.  Ameliorative effect of Alnus japonica ethanol extract on colitis through the inhibition of inflammatory responses and attenuation of intestinal barrier disruption in vivo and in vitro. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[17]  Ying Xie,et al.  Palmatine ameliorated murine colitis by suppressing tryptophan metabolism and regulating gut microbiota , 2018, Pharmacological research.

[18]  Tiehua Zhang,et al.  Beneficial Effect of Intestinal Fermentation of Natural Polysaccharides , 2018, Nutrients.

[19]  K. Takeda,et al.  Maintenance of intestinal homeostasis by mucosal barriers , 2018, Inflammation and regeneration.

[20]  K. Takeda,et al.  Maintenance of intestinal homeostasis by mucosal barriers , 2018, Inflammation and Regeneration.

[21]  S. Batra,et al.  Mouse Model of Dextran Sodium Sulfate (DSS)-induced Colitis. , 2017, Bio-protocol.

[22]  D. Kalman,et al.  Layered defense: how mucus and tight junctions seal the intestinal barrier , 2017, Journal of Molecular Medicine.

[23]  L. Peyrin-Biroulet,et al.  Ulcerative colitis , 2017, The Lancet.

[24]  Richard Hodson Inflammatory bowel disease , 2016, Nature.

[25]  W. Garrett,et al.  Gut microbiota, metabolites and host immunity , 2016, Nature Reviews Immunology.

[26]  T. Meštrović,et al.  Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients , 2016, International journal of molecular sciences.

[27]  R. D'Incà,et al.  Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut , 2015, Mediators of inflammation.

[28]  L. Menchen,et al.  A new role for reticulon-4B/NOGO-B in the intestinal epithelial barrier function and inflammatory bowel disease. , 2015, American journal of physiology. Gastrointestinal and liver physiology.

[29]  Hiroshi Suzuki,et al.  Structural insight into tight junction disassembly by Clostridium perfringens enterotoxin , 2015, Science.

[30]  M. Floch The effect of probiotics on host metabolism: the microbiota and fermentation. , 2010, Journal of clinical gastroenterology.

[31]  S. Wilhelm,et al.  A review of infliximab use in ulcerative colitis. , 2008, Clinical therapeutics.

[32]  R. Xavier,et al.  Unravelling the pathogenesis of inflammatory bowel disease , 2007, Nature.

[33]  N. Shepherd,et al.  Basiliximab for the treatment of steroid‐resistant ulcerative colitis: further experience in moderate and severe disease , 2006, Alimentary pharmacology & therapeutics.